Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Baudry E, Naoun N, Auclin E, Saldana C, Barthelemy P, Geoffrois L, Thibault C, de Vries-Brilland M, Borchiellini D, Maillet D, Hirsch L, Vauchier C, Carril-Ajuria L, Colomba E, Bernard-Tessier A, Escudier B, Flippot R, Albigès L. Baudry E, et al. Among authors: maillet d. Eur J Cancer. 2023 Nov;193:113292. doi: 10.1016/j.ejca.2023.113292. Epub 2023 Aug 18. Eur J Cancer. 2023. PMID: 37717282
Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4.
Royet A, Broutier L, Coissieux MM, Malleval C, Gadot N, Maillet D, Gratadou-Hupon L, Bernet A, Nony P, Treilleux I, Honnorat J, Liebl D, Pelletier L, Berger F, Meyronet D, Castets M, Mehlen P. Royet A, et al. Among authors: maillet d. Oncotarget. 2017 Apr 4;8(14):23750-23759. doi: 10.18632/oncotarget.16077. Oncotarget. 2017. PMID: 28423606 Free PMC article.
The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death.
Vial J, Royet A, Cassier P, Tortereau A, Dinvaut S, Maillet D, Gratadou-Hupon L, Creveaux M, Sadier A, Tondeur G, Léon S, Depaepe L, Pantalacci S, de la Fouchardière A, Micheau O, Dalle S, Laudet V, Mehlen P, Castets M. Vial J, et al. Among authors: maillet d. Cell Death Differ. 2019 Mar;26(3):443-454. doi: 10.1038/s41418-018-0128-1. Epub 2018 May 31. Cell Death Differ. 2019. PMID: 29855541 Free PMC article.
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, Gilly FN, Foll M, Fernandez-Cuesta L, Brevet M. Leblay N, et al. Among authors: maillet d. J Thorac Oncol. 2017 Apr;12(4):724-733. doi: 10.1016/j.jtho.2016.12.019. Epub 2016 Dec 27. J Thorac Oncol. 2017. PMID: 28034829 Free article.
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S. Angelergues A, et al. Among authors: maillet d. Eur J Cancer. 2014 Jun;50(9):1602-9. doi: 10.1016/j.ejca.2014.03.015. Epub 2014 Apr 8. Eur J Cancer. 2014. PMID: 24725337
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.
Beauval JB, Loriot Y, Hennequin C, Rozet F, Barthelemy P, Borchiellini D, Schlürmann Constans F, Gross E, Maillet D, Pasticier G, Pignot G, Timsit MO, Vincendeau S, Ploussard G, Sargos P. Beauval JB, et al. Among authors: maillet d. Crit Rev Oncol Hematol. 2018 Feb;122:144-149. doi: 10.1016/j.critrevonc.2017.12.012. Epub 2017 Dec 30. Crit Rev Oncol Hematol. 2018. PMID: 29458782 Review.
145 results